Can beta-lactams be re-engineered to beat MRSA?

Area of Science:

• Microbiology
• Infectious Diseases
• Pharmacology

Background:

• Methicillin-resistant Staphylococcus aureus (MRSA) is a significant global pathogen.
• MRSA resistance stems from PBP2' (PBP-2a), an altered penicillin-binding protein encoded by the mecA gene.
• Existing beta-lactams exhibit weak affinity for PBP2', necessitating new therapeutic strategies.

Purpose of the Study:

• To investigate the development of beta-lactams with enhanced affinity for PBP2'.
• To evaluate the efficacy of ceftobiprole, a novel cephalosporin targeting PBP2', against MRSA infections.

Main Methods:

• Development of beta-lactam analogues with improved PBP2' binding.
• In vitro susceptibility testing of ceftobiprole against MRSA strains.
• Clinical trials (Phase II and III) to assess ceftobiprole's efficacy and safety.

Main Results:

• Ceftobiprole demonstrates high affinity for PBP2', inhibiting MRSA at 1-2 mg/L.
• Even with strong mecA/PBP2' induction, ceftobiprole MICs remained clinically attainable (≤4 mg/L).
• Phase II trials showed a 100% cure rate in MRSA skin infections.

Conclusions:

• Ceftobiprole represents a promising therapeutic agent against MRSA.
• Its high affinity for PBP2' and clinical efficacy offer a potential advancement in treating MRSA infections.
• Further results from Phase III trials are anticipated with significant interest.